CA 72-4 serum marker-a new tool in the management of carcinoma patients

Fiorella Guadagni, Mario Roselli, Maurizio Cosimelli, Patrizia Ferroni, Antonella Spila, Francesco Cavaliere, Valerio Casaldi, Giulia Wappner, Maria Rosaria Abbolito, John W. Greiner, Jeffrey Schlom

Research output: Contribution to journalArticlepeer-review


Among the new tumor markers that have been recently proposed, CA 72-4 is of particular interest, not only for its capabilities in diagnosing and monitoring certain neoplastic diseases, but also for its excellent specificity. Several studies focused on the potential clinical usefulness ofCA 72-4 in gastrointestinal (GI) and gynecological cancer, showing a sensitivity of approximately 40% in colorectal and gastric cancer and 50% in ovarian cancer, with an overall specificity of more than 95% Longitudinal evaluations of patients with either GI or gynecological malignant diseases demonstrated that significant elevations of CA 72-4 serum levels may be predictive of recurrent disease. Moreover, the combination of CA 72-4 with other known serum markers, such as CEA and CA 19-9 for GI cancer or CA 125 for ovarian cancer, indicated that an increase in the sensitivity can be achieved without substantial changes in the overall specificity, improving the possibility of monitoring these patients. In conclusion, these results provide a strong argument for the use of CA 72-4 in the management of these neoplastic diseases.

Original languageEnglish
Pages (from-to)227-238
Number of pages12
JournalCancer Investigation
Issue number2
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'CA 72-4 serum marker-a new tool in the management of carcinoma patients'. Together they form a unique fingerprint.

Cite this